Last reviewed · How we verify
NCT06329388
Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns
Phase 1, PHASE2 trial testing TruHeight Growth Protein Shake in Growth Disorders in 32 participants. Completed in 11 August 2023.
7 July 2023
Quick facts
| Lead sponsor | TruHeight Vitamins |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 18 January 2023 |
| Primary completion | 7 July 2023 |
| Estimated completion | 11 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TruHeight Growth Protein Shake
Conditions studied
- Growth Disorders — all drugs for Growth Disorders →
- Dietary Exposure — all drugs for Dietary Exposure →
- Child Development — all drugs for Child Development →
- Bone Development Abnormal — all drugs for Bone Development Abnormal →
Sponsor
TruHeight Vitamins
Who can join
Adults 4 to 17, any sex, with Growth Disorders or Dietary Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center, randomized controlled pilot study aims to evaluate the efficacy of TruHeight Growth Protein Shake on improving growth patterns in children aged 4-17 years. Over six months, participants will consume the protein shake daily, five times a week, with outcomes measured in terms of type X collagen concentration in urine, height via a stadiometer, and body composition using an INBODY device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06329388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Growth Disorders
Currently open trials in the same condition.
- NCT06662045 — Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months · recruiting
- NCT06037473 — The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg · recruiting
- NCT05916144 — The Effect of Interaction-Based Early Education Program Applied to Grandparents on the Grandchildren's Health · NA · active not recruiting
- NCT05382637 — Growth Hormone in a Patient With a Dominant-Negative GHR Mutation · Phase 2 · active not recruiting
- NCT03761498 — Is There a Microbiome Associated With Poor Growth in Preterm Infants? · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06329388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TruHeight Vitamins
- Last refreshed: 26 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06329388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing